Cost‐Effectiveness of Preemptive Plerixafor Versus Rescue Plerixafor for Mobilization and Collection of Hematopoietic Stem Cells in Patients With Multiple Myeloma and Lymphoma
Preemptive plerixafor is a cost-effective strategy compared to rescue plerixafor, offering higher efficacy and lower ICER values, making it a clinically beneficial option despite its higher cost.
Authors
- Alessandro Gonçalves Campolina (ORCID: https://orcid.org/0000-0002-0233-0797)
- Roselene Mesquita Augusto Passos (ORCID: https://orcid.org/0000-0002-9509-5043)
- J Passos
- Leila Perobelli (ORCID: https://orcid.org/0000-0002-0643-5975)
- Vinícius F. Calsavara (ORCID: https://orcid.org/0000-0003-2332-5863)
- Cesar de Almeida‐Neto (ORCID: https://orcid.org/0000-0002-8490-4634)
- Miriam Allein Zago Marcolino (ORCID: https://orcid.org/0000-0001-5333-3173)
Institutions
- Cedars-Sinai Medical Center (US)
- Universidade Federal do Rio Grande do Sul (BR)
- Universidade de São Paulo (BR)
- Instituto do Câncer do Estado de São Paulo (BR)
- Dr. Euryclides Hospital de Jesus Zerbini (BR)
- Faculdade de Medicina de Jundiaí (BR)
- Fundação Pró-Sangue Hemocentro de São Paulo (BR)
Publication Details
- Journal
- Journal of Clinical Apheresis
- Published
- 2025-05-03
- DOI
- https://doi.org/10.1002/jca.70026
- Citations
- 1
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Universidade de São Paulo
- Faculdade de Medicina da Universidade de São Paulo